Bridging the Gaps in Lung Cancer

Narjust Florez, MD, discusses how the agenda for the Bridging the Gaps in Lung Cancer meeting evolves year to year based on emerging data and community feedback.

Noura Choudhury, MD, discusses how resistance mechanisms to tarlatamab-dlle could inform sequencing decisions in small cell lung cancer.

Jonathan Wesley Riess, MD, MS, discusses the evolving landscape of KRAS inhibitors, including the distinction between KRAS(OFF) and (ON) inhibitors.

Edward S. Kim, MD, MBA, discusses the purpose and value of the Bridging the Gaps in Lung Cancer meeting.

Xiuning Le, MD, PhD, discusses treatment selection among targeted therapies for HER2-mutant NSCLC.

David Gerber, MD, discusses the evolution of ALK TKIs and the central nervous system toxicity tradeoffs seen with later-generation agents in NSCLC.

Jay M. Lee, MD, discusses the role of ctDNA in guiding surveillance and treatment escalation decisions in resected NSCLC.

Amy L. Cummings, MD, discusses patient selection for adjuvant immunotherapy in resectable non–small cell lung cancer.

Sandip Patel, MD, discusses key unmet needs and open questions surrounding EGFR-mutant NSCLC that has transformed to SCLC.

Jyoti Malhotra, MD, MPH, discusses current knowledge of ADC efficacy in patients with NSCLC and brain metastases.

Fawzi F Abu Rous, MD, discusses evolving strategies for HER2 and MET testing in non–small cell lung cancer.

Balazs Halmos, MD, shares suggestions regarding patient selection for adjuvant therapy after neoadjuvant chemoimmunotherapy and surgery in NSCLC.

Jonathan Wesley Riess, MD, MS, outlines treatment sequencing considerations for KRAS- and BRAF-targeted therapies in NSCLC.

Ravi Salgia, MD, PhD, highlights biomarker-driven strategies in development for second-line small cell lung cancer management.

Edward S. Kim, MD, MBA, highlighted the distinct purpose of the Bridging the Gaps in Lung Cancer consensus meeting.

Triparna Sen, PhD, discusses the role of immunotherapy for the treatment of patients with small cell lung cancer.

Lyudmila A. Bazhenova, MD, discusses steps that the lung cancer field can take to improve biomarker research.

Narjust Florez, MD, discusses the importance of addressing crucial gaps in care for patients with lung cancer.

Jonathan Wesley Riess, MD, MS, discusses developments in the treatment of patients with NSCLC harboring ALK or ROS1 rearrangements.

Roy S. Herbst, MD, PhD, discusses the evolution of targeted therapies in EGFR-mutated NSCLC, as well as hurdles associated with biomarker testing.

Julia Rotow, MD, discusses existing unmet needs for patients with lung cancer and CNS metastases.

Leah Backhus, MD, MPH, FACS, discusses the evolving definition of borderline resectable lung cancer.

Erminia Massarelli, MD, PhD, MS, discusses selpercatinib and pralsetinib in treating advanced non-small cell lung cancer.

Karen L. Reckamp, MD, MS, discusses the role of amivantamab in the treatment of advanced non–small cell lung cancer.

Jacob Sands, MD, discusses updates to the role of antibody-drug conjugates in the treatment of patients with small cell lung cancer.

Fred R. Hirsch, MD, PhD, discusses the activity of HER3-directed agents in patients with non–small cell lung cancer harboring NRG1 mutations.

Julia Rotow, MD, discusses the importance of comprehensive biomarker testing for all patients with NSCLC.

Joshua K. Sabari, MD, discusses barriers to biomarker testing in patients with non–small cell lung cancer.